New combo therapy before surgery shows promise for rare liver cancer
NCT ID NCT07639528
First seen Jun 11, 2026 · Last updated Jun 16, 2026 · Updated 2 times
Summary
This study tests whether giving immunotherapy (durvalumab) and chemotherapy (cisplatin and gemcitabine) before surgery can shrink liver tumors and help prevent cancer from coming back. Some participants also receive a targeted drug (futibatinib) if their tumor has a specific genetic change. The trial enrolls 44 adults with resectable intrahepatic cholangiocarcinoma and focuses on safety and treatment completion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.